Breast Cancer

The designation, which will expedite the development and review of sacituzumab govitecan in TNBC, is based on a phase 2 trial in which the therapy induced a response rate of 31 percent in heavily pretreated patients with metastatic TNBC.

Learning to accept my body after a double mastectomy.

These data were presented in mid-December 2015.

Following doctors orders is what we're supposed to do, but sometimes it's a personal choice.

Exercise, protein, belief and visualization are my not-so-secret weapons in my life with metastatic breast cancer.

A male breast cancer survivor shares his humorous twist to health and healing.

A cancer survivor wonders if chemicals contributed to her breast cancer or melanoma.

In an interview with CURE, Anees B. Chagpar, from The Breast Center at Smilow Cancer Hospital at Yale-New Haven, shares her thoughts on the final guidelines and how they change the focus of screening.

Doing a little reflection about where I've been and how far I've come is just as important as making resolutions.

The cancer experience is different for all of us that is sometimes easy to navigate and sometimes not at all. Yet we all join the same team once we hear the words “you have cancer.” We can help each other to cope.

A five-year breast cancer survivor expresses uncertainty about discontinuing her hormone-suppressing medication.